DK0479912T3 - Fremgangsmåde til hæmning af N-endereglens forløb i levende celler - Google Patents

Fremgangsmåde til hæmning af N-endereglens forløb i levende celler

Info

Publication number
DK0479912T3
DK0479912T3 DK90911196.5T DK90911196T DK0479912T3 DK 0479912 T3 DK0479912 T3 DK 0479912T3 DK 90911196 T DK90911196 T DK 90911196T DK 0479912 T3 DK0479912 T3 DK 0479912T3
Authority
DK
Denmark
Prior art keywords
amino acid
protein
terminal
type
regulator
Prior art date
Application number
DK90911196.5T
Other languages
Danish (da)
English (en)
Inventor
Rohan T Baker
David K Gonda
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of DK0479912T3 publication Critical patent/DK0479912T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
DK90911196.5T 1989-06-30 1990-06-27 Fremgangsmåde til hæmning af N-endereglens forløb i levende celler DK0479912T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37382589A 1989-06-30 1989-06-30

Publications (1)

Publication Number Publication Date
DK0479912T3 true DK0479912T3 (da) 1994-10-10

Family

ID=23474039

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911196.5T DK0479912T3 (da) 1989-06-30 1990-06-27 Fremgangsmåde til hæmning af N-endereglens forløb i levende celler

Country Status (10)

Country Link
US (1) US5766927A (fr)
EP (1) EP0479912B1 (fr)
JP (1) JP2904921B2 (fr)
AT (1) ATE106449T1 (fr)
AU (1) AU5963290A (fr)
CA (1) CA2063400C (fr)
DE (1) DE69009476T2 (fr)
DK (1) DK0479912T3 (fr)
ES (1) ES2054365T3 (fr)
WO (1) WO1991000356A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861312A (en) * 1997-12-02 1999-01-19 California Institute Of Technology Nucleic acid encoding mammalian UBR1
AU2605600A (en) * 1999-01-11 2000-08-01 Mindset Biopharmaceuticals (Usa) Inc. Methods for regulating the stability of recombinant proteins and products usefultherein
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
AU3604800A (en) * 1999-02-26 2000-09-14 Mindset Biopharmaceuticals (Usa) Ltd. Method for regulating the stability of recombinant proteins, and antibodies and products useful therein
US7262005B1 (en) 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
EP1581174B1 (fr) * 2002-12-16 2018-04-25 GlobeImmune, Inc. Vaccins a base de levure pour immunotherapie
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
ES2709125T3 (es) * 2006-09-26 2019-04-15 Massachusetts Inst Technology Péptidos autoensamblantes modificados
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
US8530636B2 (en) 2008-05-07 2013-09-10 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells in vivo using synthetic small molecules
US8999896B2 (en) * 2010-01-15 2015-04-07 California Institute Of Technology Discovery and applications of the proteolytic function of N-terminal acetylation of cellular proteins
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3180326A1 (fr) 2020-04-20 2021-10-28 Vestaron Corporation Polypeptides variants d'u1-agatoxine-ta1b stables a la proteolyse pour la lutte antiparasitaire
IL297738A (en) 2020-05-01 2022-12-01 Vestaron Corp Insecticide combinations
AR125258A1 (es) 2021-04-01 2023-06-28 Vestaron Corp Polipéptidos con mutaciones de av3 para el control de plagas
CA3238619A1 (fr) 2021-11-29 2023-06-01 Michael Gerber Compositions pharmaceutiques pour le traitement de la douleur viscerale
WO2023122805A1 (fr) 2021-12-20 2023-06-29 Vestaron Corporation Procédé de pression de sélection par sorbitol
WO2023225555A1 (fr) 2022-05-18 2023-11-23 Vestaron Corporation Variants peptidiques d'actx pesticides
WO2023245100A1 (fr) 2022-06-17 2023-12-21 Vestaron Corporation Peptides variants de ncr13 antimicrobiens
WO2024026406A2 (fr) 2022-07-29 2024-02-01 Vestaron Corporation Peptides actx de nouvelle génération

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512979A (en) * 1981-03-23 1985-04-23 Merck & Co., Inc. Dipeptides containing thialysine and related amino acids as antihypertensives
US4514391A (en) * 1983-07-21 1985-04-30 E. R. Squibb & Sons, Inc. Hydroxy substituted peptide compounds
US4551445A (en) * 1983-10-14 1985-11-05 The Medical College Of Ohio Derivatives of arginine vasopressin antagonists
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
JP2612874B2 (ja) * 1986-10-02 1997-05-21 マサチユセツツ・インスチチユート・オブ・テクノロジー タンパク質の代謝的安定性を調節する方法
US5108919A (en) * 1988-06-24 1992-04-28 Genentech, Inc. Dna sequences encoding yeast ubiquitin hydrolase
CH680013A5 (fr) * 1988-09-19 1992-05-29 Mathias Och

Also Published As

Publication number Publication date
CA2063400A1 (fr) 1990-12-31
AU5963290A (en) 1991-01-17
DE69009476D1 (de) 1994-07-07
EP0479912B1 (fr) 1994-06-01
JP2904921B2 (ja) 1999-06-14
ATE106449T1 (de) 1994-06-15
US5766927A (en) 1998-06-16
CA2063400C (fr) 1997-07-15
ES2054365T3 (es) 1994-08-01
EP0479912A1 (fr) 1992-04-15
DE69009476T2 (de) 1994-12-22
WO1991000356A1 (fr) 1991-01-10
JPH04506298A (ja) 1992-11-05

Similar Documents

Publication Publication Date Title
DK0479912T3 (da) Fremgangsmåde til hæmning af N-endereglens forløb i levende celler
Gregory et al. The primary structure of human urogastrone
ATE113063T1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
Reed et al. Sequence of residues 400--403 of bovine serum albumin.
DE112006000677A5 (de) Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
DE3486154D1 (de) Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung.
KR850008681A (ko) 합성펩티드의 제조방법
EP0451867A1 (fr) Antagonistes d'hormone parathyroide
ATE24919T1 (de) Menschliches pankreatisches grf.
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
Han et al. The covalent structure of beef heart myoglobin
DE3875538D1 (de) Aminoluciferine, verfahren zu deren herstellung und ihre verwendung.
DE3261304D1 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
ATE146188T1 (de) Substituierungsanaloge von magaininpeptiden
DK0446315T3 (da) Fremgangsmåde til fremstilling af PAI-2
NO953286L (no) Benstimulerende faktor
ATE124955T1 (de) Substrat-peptide.
Martin et al. Sequence homologies between p36, the substrate of pp60src tyrosine kinase and a 67 kDa protein isolated from bovine aorta
Marquis et al. Stoichiometry and structure of a complex of acidic ribosomal proteins
Gish Studies on the Amino Acid Sequence of Tobacco Mosaic Virus (TMV) Protein. IV. The Amino Acid Sequences of an Eicosapeptide and a Heptadecapeptide Isolated from a Tryptic Digest of TMV Protein1
Hackeng et al. Chemical synthesis of human protein S thrombin‐sensitive module and first epidermal growth factor module
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
Foltmann The N-terminal and C-terminal amino acid sequence of calf rennin
ATE25984T1 (de) Pharmakologisch aktive peptide.
Seyer et al. Covalent structure of collagen: Amino acid sequence of three cyanogen bromide-derived peptides from human α1 (V) collagen chain